BIOMAT Database Logo BIOMAT Database Logo

Retention rate of Gabapentin in children with intractable epilepsies at 1 year. 2012

J K A Mills, and N E Ruslan, and T G Lewis, and K Mughal, and I Ali, and A Ugar, and E Wassmer, and A Siddiqua, and R Gupta, and S R Mordekar, and R Sharma, and L Sasidharan, and W P Whitehouse
School of Clinical Sciences, University of Nottingham, UK.

Gabapentin (GAB) is a newer second-line antiepileptic drug (AED) used in children. This is a multi-centre retrospective observational study of the efficacy, tolerability and retention rate in 105 children, aged 0-17.5 years (mean 10.1) over a 14 year period. The median age of epilepsy onset was 2.5 years (range 0-14.6). 72% started GAB as at least the 3rd AED, with 43% having been withdrawn from at least 2 AEDs. 77% had focal and 52% symptomatic epilepsies. The maintenance doses for GAB ranged 6.0-87.3 mg/kg/day (mean 43.7). The study comprised 157 person-treatment years for GAB. GAB was well tolerated with 55% remaining on treatment beyond 1 year. No serious adverse events were reported whilst on GAB, but 39% reported possibly and probably related adverse events. Seizure improvement (<50% seizure frequency compared to baseline) at more than 12 months of treatment, was reported in 35% of patients starting GAB, including 6% who remained seizure free. The results demonstrated the efficacy and tolerability of GAB in children with difficult to treat epilepsies, and a good response to treatment beyond 12 months, in both focal and generalised epilepsies.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003509 Cyclohexanecarboxylic Acids Carboxylic acid derivatives of cyclohexane. Acids, Cyclohexanecarboxylic
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D005260 Female Females
D005680 gamma-Aminobutyric Acid The most common inhibitory neurotransmitter in the central nervous system. 4-Aminobutyric Acid,GABA,4-Aminobutanoic Acid,Aminalon,Aminalone,Gammalon,Lithium GABA,gamma-Aminobutyric Acid, Calcium Salt (2:1),gamma-Aminobutyric Acid, Hydrochloride,gamma-Aminobutyric Acid, Monolithium Salt,gamma-Aminobutyric Acid, Monosodium Salt,gamma-Aminobutyric Acid, Zinc Salt (2:1),4 Aminobutanoic Acid,4 Aminobutyric Acid,Acid, Hydrochloride gamma-Aminobutyric,GABA, Lithium,Hydrochloride gamma-Aminobutyric Acid,gamma Aminobutyric Acid,gamma Aminobutyric Acid, Hydrochloride,gamma Aminobutyric Acid, Monolithium Salt,gamma Aminobutyric Acid, Monosodium Salt
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077206 Gabapentin A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME. 1-(Aminomethyl)cyclohexaneacetic Acid,Apo-Gabapentin,Convalis,Gabapentin Hexal,Gabapentin Stada,Gabapentin-Ratiopharm,Neurontin,Novo-Gabapentin,PMS-Gabapentin,Apo Gabapentin,ApoGabapentin,Gabapentin Ratiopharm,Novo Gabapentin,NovoGabapentin

Related Publications

J K A Mills, and N E Ruslan, and T G Lewis, and K Mughal, and I Ali, and A Ugar, and E Wassmer, and A Siddiqua, and R Gupta, and S R Mordekar, and R Sharma, and L Sasidharan, and W P Whitehouse
Retention rate of clobazam, topiramate and lamotrigine in children with intractable epilepsies at 1 year.
June 2011, Seizure,
J K A Mills, and N E Ruslan, and T G Lewis, and K Mughal, and I Ali, and A Ugar, and E Wassmer, and A Siddiqua, and R Gupta, and S R Mordekar, and R Sharma, and L Sasidharan, and W P Whitehouse
Retention rate of levetiracetam in children with intractable epilepsy at 1 year.
March 2007, Seizure,
J K A Mills, and N E Ruslan, and T G Lewis, and K Mughal, and I Ali, and A Ugar, and E Wassmer, and A Siddiqua, and R Gupta, and S R Mordekar, and R Sharma, and L Sasidharan, and W P Whitehouse
Retention rate of zonisamide in intractable epilepsy.
May 2015, Acta neurologica Scandinavica,
J K A Mills, and N E Ruslan, and T G Lewis, and K Mughal, and I Ali, and A Ugar, and E Wassmer, and A Siddiqua, and R Gupta, and S R Mordekar, and R Sharma, and L Sasidharan, and W P Whitehouse
Use of lamotrigine in medically intractable epilepsies in children.
January 2008, Medicinski arhiv,
J K A Mills, and N E Ruslan, and T G Lewis, and K Mughal, and I Ali, and A Ugar, and E Wassmer, and A Siddiqua, and R Gupta, and S R Mordekar, and R Sharma, and L Sasidharan, and W P Whitehouse
Vagus nerve stimulation for children and adolescents with intractable epilepsies.
February 2001, Pediatrics international : official journal of the Japan Pediatric Society,
J K A Mills, and N E Ruslan, and T G Lewis, and K Mughal, and I Ali, and A Ugar, and E Wassmer, and A Siddiqua, and R Gupta, and S R Mordekar, and R Sharma, and L Sasidharan, and W P Whitehouse
[Molecular genetics of intractable epilepsies].
May 2014, No to hattatsu = Brain and development,
J K A Mills, and N E Ruslan, and T G Lewis, and K Mughal, and I Ali, and A Ugar, and E Wassmer, and A Siddiqua, and R Gupta, and S R Mordekar, and R Sharma, and L Sasidharan, and W P Whitehouse
Intractable epilepsies. An open trial with Clobazam.
February 1989, Acta neurologica,
J K A Mills, and N E Ruslan, and T G Lewis, and K Mughal, and I Ali, and A Ugar, and E Wassmer, and A Siddiqua, and R Gupta, and S R Mordekar, and R Sharma, and L Sasidharan, and W P Whitehouse
Comparative role of neuropsychological testing in the presurgical evaluation of children with medically intractable epilepsies.
July 2009, Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery,
J K A Mills, and N E Ruslan, and T G Lewis, and K Mughal, and I Ali, and A Ugar, and E Wassmer, and A Siddiqua, and R Gupta, and S R Mordekar, and R Sharma, and L Sasidharan, and W P Whitehouse
[Effect of melatonin on intractable epilepsies].
December 2004, Orvosi hetilap,
J K A Mills, and N E Ruslan, and T G Lewis, and K Mughal, and I Ali, and A Ugar, and E Wassmer, and A Siddiqua, and R Gupta, and S R Mordekar, and R Sharma, and L Sasidharan, and W P Whitehouse
[Neuropsychological profile of intractable partial epilepsies].
June 2004, Revue neurologique,
Copied contents to your clipboard!